Principal-Investigator - Amgen Protocol# 20050154:  Phase 2,
Randomized, Double Blind, Placebo-Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Chemotherapy-Induced Thrombocytopenia In Subject with Advanced Non-Small Cell
Lung Cancer Already Receiving Gemcitabine and Platinum.

Principal-Investigator for Millennium Pharma., : Protocol # C05009:
Phase IIIB, randomized study of three treatment regimens in subjects with previously untreated Multpile Myeloma who are not considered candidates High Dose Chemotherapy and Autologous Stem Cell Transplatation.  Velcade, Thalomide & Dexamethasone (VTD) vs. Velcade and Dexamethasone (VD)
Vs. Velcade, Melphalan, and Prednisone (VMP).

Sub-Investigator – NSABP-B-42:  A Clinical Trial to Determine the Efficacy o Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Follow by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer.

Sub-Investigator - E5103: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer.

Sub-Investigator - IBCSG-2402:  Phase III Randomized Study of Ovarian Function Suppression in Combination With Tamoxifen Versus Ovarian Function Suppression in Combination With Exemestane Versus Tamoxifen Alone in Premenopausal Women With Endocrine-Responsive Breast Cancer.

Sub-Investigator - E2Z04: Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance.  For patients diagnosed with breast cancer between 18-45 years old or between 55-78 years old and patient received chemotherapy 3-8 years ago and is currently disease free. 

Sub-Investigator - NSABP-B-39: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer. 

Sub- Investigator - S0500: A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment.

Sub-Investigator - E5597: Randomized Phase III Chemoprevention Trial of Selenium Supplements in Persons with Resected Stage I NSCLC.

Sub-Investigator - S0421: Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer. 

Sub-Investigator - RTOG-0521: A Phase III Protocol of Androgen Suppression (AS) and 3DCTR/IMRT vs AS and 3DCTR/IMRT Followed by Chemotherapy With Docetaxel and Prednisone for Localized, High-Risk, Prostate Cancer.

Sub-Investigator - RTOG-0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma. 

Sub-Investigator - N0574-Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases.

Sub-Investigator - Novartis Pharmaceuticals Corp: A prospective, Randomized, Multi-Center, 3 arm of the continued efficacy and  safety of Zometa in patients with documented bone metastases from Breast cancer.  Protocol #CZOL446E2352.

Principal-Investigator - Amgen Protocol# 20050154:  Phase 2,
Randomized, Double Blind, Placebo-Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Chemotherapy-Induced Thrombocytopenia In Subject with Advanced Non-Small Cell Lung Cancer Already Receiving Gemcitabine and Platinum.

Sub-investigator – Aventis Pharma and Breast Cancer International Research Group (BCIRG): A  Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC à) with Doxorubicin and Cyclophos- -phamide Followed by Docetaxel and Trastuzumab (ACàH) and with  Docetaxel, Platinum Salt and Trastuzumab (TCH) in the Treatment of Node Positive and High Risk Node Negative Adjuvant Patients with Operable Breast Cancer Containing the HER2NEU Alternation, Protocol #BCIRG 006.

Sub-investigator – Genentech, Inc.:  A Multicenter, Open-Label, Phase IIIb Trial of Tarceva™ (Erlotinib Hydrochloride) in Patients with Advanced Non-Small Cell Lung Cancer, Protocol #OS13199g-A1.

Sub-Investigator ECOG-endorsed study:  IBCSG2502 – Phase III Trial evaluating the role of Exemestane Plus GnRH  analogue as Adjuvant Therapy for Pre-menopausal Women with Endocrine Responsive Breast Cancer.

Sub-investigator – Genentech, Inc. and Biogen Idec:  The National Lymphocare Study:  An Observational Study of Treatment, Outcomes, and Prognosis in Patients with Follicular Non-Hodgkin’s Lymphoma, Protocol #U2963n.

Sub-Investigator ECOG endorsed study:  E1Y97:  Mapping Interactive Cancer Susceptibility in Siblings with the same Cqncer (Breast, Prostate, Lung or Colon).

Principal Investigator ECOG endorsed study S9917 L-Selenium-Based Chemo prevention of Prostate Cancer among Men with High Grade Prostatic Intraepithelial Neoplasia.

Sub-Investigator ECOG endorsed study:  CALGB 80101-Phase III Intergroup Trial of Adjuvant Chemo Radiation after Resection of Gastric or Gastroesopahgeal Adnocarcinoma.

Sub-Investigator ECOG endorsed study:  RTOG0214-Phase III
Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients with Locally  Advanced Non-Small Cell Lung Cancer.

Principal Investigator - Astra-Zeneca Pharmaceuticals: An Expanded Access Clinical Program  with ZD1839 (IRESSA™) for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC), Protocol #1839IL/0050.